- 如果您对该产品感兴趣的话，可以
- 产品名称：AKT1/3 (Phospho-Tyr437/434) antibody
- 产品型号：
- 产品展商：immunoclone
- 产品文档：无相关文档
- 发布时间：2018-09-06
- 在线询价
简单介绍
AKT1/3 (Phospho-Tyr437/434) antibody迅速增长的产品线包括一抗、二抗、**测定及细胞检测试剂盒、蛋白/多肽、激动剂/拮抗剂/活化剂/抑制剂及裂解物等。AKT1/3 (Phospho-Tyr437/434) antibody严格的质量控制和验证实验包括各种不同的应用：WB、细胞**荧光、**组化、流式细胞术、ELISA、CHIP、IP和peptide array。
产品描述
AKT1/3 (Phospho-Tyr437/434) antibodyProduct Profile
|
Product Name
|
Rabbit anti-AKT1/3 (Phospho-Tyr437/434) polyclonal antibody
|
|
Antibody Type
|
Primary Antibodies
|
|
Immunogen
|
The antiserum was produced against synthesized peptide derived from human AKT1/3 around the phosphorylation site of Tyr437/434.
|
AKT1/3 (Phospho-Tyr437/434) antibodyKey Feature
|
Clonality
|
Polyclonal
|
|
Host Species
|
Rabbit
|
|
Tested Applications
|
WBIHCELISA
|
|
|
WB:1:500~1:1000
IHC:1:50~1:100
ELISA:1:20000
|
|
Species Reactivity
|
HumanMouseRat
|
|
Concentration
|
1 mg/ml
|
|
Purification
|
Affinity purified
|
AKT1/3 (Phospho-Tyr437/434) antibodyTarget Information
|
Gene Symbol
|
AKT1
|
|
Gene Synonyms
|
RAC-PK-alpha
Protein kinase B
PKB
C-AKT
More
|
AKT1/3 (Phospho-Tyr437/434) antibodyDatabase Links
|
Entrez Gene
|
207
208
10000
|
|
Unigene
|
525622
631535
498292
|
|
OMIM
|
164730
164731
611223
|
|
SwissProt ID
|
P31749
Q9Y243
|
AKT1/3 (Phospho-Tyr437/434) antibodyApplication
-
Immunohistochemical
Immunohistochemistry analysis of paraffin-embedded human brain, using AKT1/3 (Phospho-Tyr437/434) Antibody. The picture on the right is treated with the synthesized peptide.
-
Western blot
Western blot analysis of extracts from K562 cells treated with insulin 0.01U/ml 15', using AKT1/3 (Phospho-Tyr437/434) Antibody. The lane on the right is treated with the synthesized peptide
|
Application Notes
|
WB:1:500~1:1000
IHC:1:50~1:100
ELISA:1:20000
|
Additional Information
|
Form
|
Liquid
|
|
Storage Instructions
|
store at -20°C. Avoid repeated freeze / thaw cycles
|
|
Storage Buffer
|
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
|
